Pharmacological treatment of stable angina – Conventional and novel anti-anginal agents
Managing chronic stable angina pectoris continues to represent a challenge to the practicing physician. Novel anti-angina agents have been incorporated to our therapeutic arsenal in recent years. Ranolazine is one of such agents with novel mechanisms of actions. This programme focuses on the indications, contraindications and practical use of this agent in clinical practice. General practitioners, hospital consultants and clinical-academics contribute their expert views and practical suggestions in this online educational programme.
Related articles
01/15/2018 - Percutaneous Coronary Intervention (PCI): a therapeutic myth? - Prof JC Kaski, St George's, University of London, UK
01/02/2017 - Recurrent or persistent angina after coronary artery revascularisation and stent implantation - Prof Juan Carlos Kaski, St George's, University of London, UK
06/27/2016 - Ranolazine for management of microvascular angina - Prof Juan Carlos Kaski, St George's, University of London, UK
04/04/2016 - Perioperative beta-blockade in non-cardiac surgery: Harmful or helpful? - Dr Rachel Bastiaenen, PhD, St George's University of London, St George's Hospital London, UK
02/29/2016 - Marfan Syndrome - Dr Anne Child, St George's, University of London, UK
12/14/2015 - Do beta blockers increase cardiovascular risk in patients with stable angina pectoris? - Professor Juan Carlos Kaski, St George’s University of London, UK
11/10/2015 - Diagnosing angina: key differences between men and women - Dr Noel Bairey-Merz, Director, Barbra Streisand Women’s Heart Center and Preventive Cardiac Center; Professor of Medicine, Heart Institute, Cedars-Sinai Medical Center and UCLA, USA.
09/02/2015 - Long QT syndrome and epilepsy -
Leave a Reply
You must be logged in to post a comment.